Abstract
On the basis of the chemical and biological data, the material basis of ACE inhibitory activity for the active part was the phenolic constituents. However, the flavonoid compounds were responsible for the anti-platelet aggregation. The primary structure and activity relationship were also discussed respectively.
Introduction
Tamarix hohenackeri Bunge is a resilient salt cedar native to the deserts of Xinjiang, China. While it is well-known as the host plant for the precious medicinal herb Herba Cistanches, its own pharmacological potential has remained largely unmapped. Given that cardiovascular diseases—driven by hypertension and abnormal blood clotting (thrombosis)—are leading causes of global mortality, there is significant interest in identifying natural alternatives to synthetic drugs like Captopril and Aspirin. This study systematically screens T. hohenackeri for compounds that inhibit Angiotensin-Converting Enzyme (ACE) and platelet aggregation.
Methodology
The researchers employed a bioassay-directed separation strategy to isolate bioactive compounds. Aerial parts of the plant were extracted with 70% ethanol and partitioned into petroleum ether, ethyl acetate (EtOAc), and n-butanol fractions. The highly active EtOAc fraction underwent further purification using various chromatographic techniques, including Silica gel, Sephadex LH-20, Medium-Pressure Liquid Chromatography (MPLC), and High-Performance Liquid Chromatography (HPLC).
Structural identification of the isolated compounds was achieved through High-Resolution Electrospray Ionization Mass Spectrometry (HR-ESI-MS) and Nuclear Magnetic Resonance (NMR) spectroscopy (1D and 2D techniques such as HMBC and NOESY). Biological activity was assessed using an HPLC-based ACE inhibition assay and an ADP-triggered platelet aggregation assay using rat plasma.
Key Results and Discussion
The study successfully isolated 14 bioactive compounds, including a novel triterpenoid lactone: 3α-hydroxyolean-28,13-olide (1).
Extract Potency
The ethyl acetate (EtOAc) extract demonstrated exceptional bioactivity, achieving 99.2% ACE inhibition at 100 mg/mL and 97.21% platelet inhibition at 400 µg/mL. The dose-dependent nature of this inhibition across different extracts is shown below.
Structural Elucidation of a New Compound
A significant highlight of the chemical analysis was the discovery of compound 1. Its structure was confirmed through detailed 2D NMR analysis, establishing it as a new member of the triterpenoid lactone family within the Tamarix genus. Although it did not show activity in the specific ACE/platelet assays, its discovery adds to the known chemical diversity of the species.
Functional Specialization and SAR
The research revealed a clear "division of labor" among the plant's secondary metabolites:
- ACE Inhibition: Phenolic constituents, particularly gallic acid (11) and 3,5-dihydroxy-4-methoxybenzoic acid (10), were the primary drivers. Structure-activity relationship (SAR) analysis suggested that benzoic acids with 3,5-dihydroxy substitutions are particularly potent.
- Anti-platelet Activity: Flavonoids such as Chrysoeriol (7) and Dillenetin (5) were most effective. Notably, Chrysoeriol (50.36% inhibition at 200 µM) outperformed the positive control, Aspirin (34.01% at 1650 µM). The presence of a 3'-methoxyl group on the flavonoid skeleton appears critical for high potency.
Conclusion
This study provides a molecular rationale for the potential use of T. hohenackeri in treating hypertension and thrombosis. While the laboratory results are promising, further in vivo studies are required to evaluate the bioavailability and clinical efficacy of these compounds. The discovery of the novel triterpenoid lactone also opens avenues for screening against other therapeutic targets, such as anti-inflammatory or anti-cancer pathways.
Summary updated